Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on Connect Biopharma Holdings, retaining the price target of $7.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Brandon Folkes has given his Buy rating due to a combination of factors that highlight Connect Biopharma Holdings’ promising developments and strategic decisions. The company has initiated two Phase 2 Seabreeze STAT trials to evaluate the efficacy of rademikibart in treating acute exacerbations of asthma and COPD, with results expected in the first half of 2026. The trials target a patient subgroup that has previously shown positive responses to the treatment, indicating potential success.
Additionally, Connect Biopharma has presented encouraging data from its chronic asthma studies, demonstrating significant improvements in lung function and reduced exacerbations. The company’s strategic moves, such as the submission of a new drug application by its partner Simcere in Greater China and plans for a direct Nasdaq listing, further strengthen its position. With a solid financial runway extending into 2027, Connect Biopharma is well-positioned for growth, justifying the Buy rating and a $7 price target.